Bildkälla: Stockfoto

Lipigon: Safe Profile and Target Engagement - Redeye

Redeye comments on the topline result of the phase I trial of Lipisense, which demonstrated a favourable safety profile and proof of mechanism.

Redeye comments on the topline result of the phase I trial of Lipisense, which demonstrated a favourable safety profile and proof of mechanism.
Börsvärldens nyhetsbrev
ANNONSER